Targeting of the Complement System in Geographic Atrophy: New Insights and Emerging Options for Treatment

Author(s)/Faculty: Caroline Baumal, MD; Nathan C. Steinle, MD
Release Date: 11/30/2021Expiration Date: 11/29/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: LectureProvider:
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that results in a progressive and irreversible loss of visual function. Dysregulation of the compliment pathway has been implicated in the development of AMD and GA, and genetic variants of several complement factor genes have been identified as risk factors for these conditions. Currently there are no approved therapies for the management of GA, but promising clinical studies are ongoing to evaluate agents that target components of the complement pathway. These emerging therapies have the potential to delay progression of GA and improve GA outcomes. In this CME activity, experts in the field examine the role of the compliment pathway in AMD as well as evaluate the clinical efficacy of emerging therapies that target the complement cascade for the management of GA secondary to AMD.